trial

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

NCTId NCT01082250
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 52 (estimated)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
52 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2008-07
Primary completion
2008-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Lev G Gertsik, MDPrincipal Investigator

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
52
Phase
PHASE1
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lev G Gertsik, MD
person